How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries
TEST_code
|
CME Activity Information |
|
Release Date: |
October 03, 2007 |
|
Most Recent Review: |
October 03, 2007* |
|
Most Recent Update: |
October 03, 2007 |
|
Date Credit Expires: |
October 03, 2009 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here
to learn more about our review process. |
Instructions for Participation
- Read the following information before beginning the educational activity
and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive
the credit or participation certificate
*The CME quiz and evaluation must be completed by October 3, 2009, in order
to receive the credit or participation certificate.
Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine
in breast cancer and are involved in providing patient care in a cancer care environment.
Learning Objectives
After completing this course, the reader should be able to:
- Discuss the possibilities for preserving fertility in women exposed to chemotherapy.
- List the possible mechanisms put forward to explain the beneficial effect
of GnRH agonists in minimizing the gonadotoxic effect of chemotherapy, in
particular that of alkylating agents.
- Identify the advantages and possible risks and shortcomings of each of the
proposed methods for fertility preservation in women exposed to gonadotoxic
chemotherapy.
- Discuss the possibility of combining several methods to maximize the chances
of fertility preservation in these patients.
- Explain the gender differences between male and female patients regarding
the methods of fertility preservation.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the School of Medicine
of The University of North Carolina at Chapel Hill and The Oncologist.
The School of Medicine of The University of North Carolina at Chapel Hill is accredited
by the ACCME to provide continuing medical education for physicians.
The School of Medicine of The University of North Carolina at Chapel Hill designates
this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™.
Physicians should only claim credit commensurate with the extent of their participation
in the activity.
Commercial Support
Non-governmental supporters of this activity: Abraxis BioScience,
AstraZeneca, Bristol-Myers Squibb Oncology, Merck, Pfizer, and sanofi-aventis
Disclosure Policy
In compliance with the Standards of the ACCME, it is the policy of the School
of Medicine of The University of North Carolina at Chapel Hill to ensure balance,
independence, objectivity, and scientific rigor in all of its educational activities
and to include information free of commercial bias and based on the best evidence
available. All individuals in a position to influence the content of this activity
have disclosed relevant financial interests or relationships of their own, their
spouse/partner, or their worksite, with manufacturers or providers of commercial
products, services, technology, or programs; and disclosed relationships with
current non-governmental supporters of the activity. The faculty and planners
have indicated that they have no relevant commercial relationships. For a list
of the faculty and planners, please visit the Editorial Board online at http://cme.theoncologist.com/misc/edboard.shtml.
All information is submitted and reviewed and found to be scientifically rigorous,
based on the best available evidence, fair and balanced, and free of commercial
bias. All the recommendations involving clinical medicine in this CME activity
are based on evidence that is accepted within the profession of medicine as
adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported or used in CME in
support or justification of a patient care recommendation conforms to the generally
accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's
anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml.
All manuscripts are reviewed by the Editorial Board with ad hoc assistance from
two or more external experts in the field. All final publication decisions are
made by the Editorial Board. The acceptance of a manuscript is based on its
originality and importance to the field as assessed by the Editors.
Author Disclosure(s)
Zev Blumenfeld, M.D.
Credentials: Department of Obstetrics and Gynecology, Rambam
Medical Center, Technion-Faculty of Medicine, Haifa, Israel. Telephone:
972-4-8542577; Fax: 972-4-8543746; E-mail:
bzeev{at}techunix.technion.ac.il
or z_blumenfeld{at}rambam.health.gov.il.
Disclosures: The author has indicated no relevant commercial relationships. Also, the author has indicated that he discusses the unlabeled, investigational, or alternative use(s) GnRH-agonist [Decapeptyl] CR1 manufactured by Ferring [Germany] for fertility preservation.
Hardware/Software Requirements
The Oncologist CME Online supports
the following browsers: Current production versions of Opera, Safari, Firefox,
Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh
version of Explorer was discontinued in June 2003, and is not supported.
Other Links
Disclaimer
Privacy statement
Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: ampcme-feedback{at}highwire.stanford.edu
Copyright © 2008 by AlphaMed Press.